Reduced cGMP concentration · Verminderte cGMP-Konzentration · cGMP-Mangel · Decreased cyclic guanosine monophosphate · Low cGMP levels · PDE5A:E90K · Canine PDE5A polymorphism
This is a benign genetic variation, or polymorphism, that affects how a dog processes certain medications like sildenafil rather than causing a physical disease. It involves a change in the PDE5A gene, which is related to cellular signaling pathways. This variation does not cause any organ damage or clinical illness.
Because this genetic variation is completely benign, affected dogs do not show any symptoms or health issues. There is no age of onset, and the dog's vision and general health remain entirely normal.
No treatment or medical management is necessary for this condition. There are no associated healthcare costs, resulting in an expected lifetime cost of 0 EUR.
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
More conditions affecting the Eyes.